2020 American Transplant Congress
Unrealized Potential Utilization of HCV+ Deceased-Donor Kidneys and Livers
*Purpose: In the era of new, direct-acting antiviral therapy for hepatitis C virus (HCV), HCV+ deceased-donor organs can be transplanted into HCV- recipients with excellent…2020 American Transplant Congress
Transplantation of HCV Positive Kidneys Confers Excellent Outcomes for HCV Infected and Uninfected Recipients
Montefiore Medical Center, Bronx, NY
*Purpose: Hepatitis C positive (HCV+) donor kidneys were previously transplanted only into HCV infected recipients (D+/R+). Availability of direct acting anti-virals (DAA) has facilitated the…2020 American Transplant Congress
The Trend of Non-Utilization and Decline of Hepatitis C Virus Antibody-Positive Deceased Donor Kidneys
*Purpose: With more transplant centers are accepting hepatitis C virus infected (HCV+) deceased donor kidneys (dHCV+), the trend of non-utilization and decline of these organs…2020 American Transplant Congress
Hepatitis C and Racial Disparity in Liver Transplant Waitlist Additions: Separate Not Equal
*Purpose: In 2014, direct-acting antivirals (DAAs) became available as a treatment option for Hepatitis C Virus (HCV) with successful results. Since the implementation of DAAs,…2020 American Transplant Congress
Survey of Clinician Opinions on Use of Organ Transplants from Hepatitis C Virus Positive Donors: Identifying & Overcoming Barriers
*Purpose: Increasing the use of Hepatitis C Virus (HCV) viremic (Nucleic Acid Testing (NAT)+) donor organs for HCV uninfected (HCV-) patients is a potential approach…2020 American Transplant Congress
Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes
*Purpose: Increased utilization of hepatitis C virus infected organs could reduce the supply demand mismatch in organ transplantation. At this time, there is little data…2020 American Transplant Congress
Re-Transplantation Outcomes in the United States Before and after DAA-Introduction
Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: The success of direct-acting antiviral (DAA) therapy has led to the widespread treatment of HCV and near-universal cure for chronically infected patients and improved…2020 American Transplant Congress
Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous trials in kidney transplantation (KT) have described a 12-week course of direct-acting anti-viral drugs (DAA) to treat HCV transmission from infected donors to…2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…2020 American Transplant Congress
Utilization of Hepatitis C Positive Organs in Kidney Transplantation
Ochsner Medical Center, New Orleans, LA
*Purpose: The efficacy of direct acting antivirals (DAAs) in HCV has cleared the path for the use of HCV positive donor kidneys into negative recipients.…
American Transplant Congress abstracts